Tarsier Pharma Ltd. (TARX)

Tarsier Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	Dec 31, 2025	Dec 31, 2024
Selling, General & Admin	0.54	0.36
Research & Development	2.01	2.03
Operating Expenses	2.55	2.4
Operating Income	-2.55	-2.4
Interest Expense (Income)	2.52	0.06
Other Expense (Income)	-10.14	-4.91
Pretax Income	5.07	2.46
Net Income	5.07	2.46
Net Income Growth	106.43%	-
Free Cash Flow	-1.32	-1.91
EBITDA	7.59	2.52
Depreciation & Amortization	0.01	0.01
EBIT	7.59	2.51

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).